Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Financial Statements

2 Followers

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H's market cap is currently HK$17.24B. The company's EPS TTM is HK$-0.169; its P/E ratio is 19.65; and it has a dividend yield of 5.23%. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is scheduled to report earnings on March 30, 2026, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Mar 22
Income Statement
Total Revenue	¥ 5.48B	¥ 5.28B	¥ 5.45B	¥ 7.16B	¥ 6.37B
Gross Profit	¥ 1.74B	¥ 1.76B	¥ 1.80B	¥ 2.33B	¥ 2.03B
Operating Income	¥ 635.97M	¥ 741.31M	¥ -238.11M	¥ 1.14B	¥ 773.20M
EBITDA	¥ 846.59M	¥ 1.20B	-	¥ 1.37B	¥ 726.64M
Net Income	¥ 349.49M	¥ 646.74M	-	¥ 727.43M	¥ 240.79M
Balance Sheet
Cash & Short-Term Investments	¥ 2.83B	¥ 2.56B	¥ 2.27B	¥ 3.45B	¥ 3.93B
Total Assets	¥ 16.63B	¥ 17.34B	¥ 19.20B	¥ 20.81B	¥ 19.11B
Total Debt	¥ 2.11B	¥ 2.98B	¥ 3.78B	¥ 6.46B	¥ 5.65B
Net Debt	¥ 762.72M	¥ 1.29B	¥ 1.93B	¥ 4.33B	¥ 2.71B
Total Liabilities	¥ 4.55B	¥ 5.14B	¥ 7.22B	¥ 8.41B	¥ 7.58B
Stockholders' Equity	¥ 12.03B	¥ 12.15B	¥ 11.91B	¥ 12.31B	¥ 11.41B
Cash Flow
Free Cash Flow	¥ 1.59B	¥ 1.99B	¥ -46.66M	¥ -979.03M	¥ -200.49M
Operating Cash Flow	¥ 1.71B	¥ 2.19B	¥ 398.22M	¥ -756.61M	¥ -6.63M
Investing Cash Flow	¥ -872.75M	¥ -415.05M	¥ 1.22B	¥ 249.84M	¥ 719.93M
Financing Cash Flow	¥ -1.09B	¥ -2.14B	¥ -1.21B	¥ 329.56M	¥ -501.08M

Currency in CNY

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Earnings and Revenue History

Income Statement >

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Debt to Assets

Balance Sheet >

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Cash Flow

Cash Flow >

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Forecast EPS vs Actual EPS

Earnings >